Welcome to our dedicated page for Alx Oncology Holdings news (Ticker: ALXO), a resource for investors and traders seeking the latest updates and insights on Alx Oncology Holdings stock.
ALX Oncology Holdings Inc. (Nasdaq: ALXO) is a clinical-stage biotechnology company whose news flow centers on the development of investigational cancer therapies. The company regularly issues updates on its lead CD47 inhibitor, evorpacept, and its EGFR-targeted antibody-drug conjugate, ALX2004, as these programs advance through clinical and preclinical milestones.
News about ALX Oncology often covers clinical trial progress for evorpacept in HER2-positive gastric and gastroesophageal cancers, HER2-positive metastatic breast cancer and indolent B-cell non-Hodgkin lymphoma. Press releases detail study designs, enrollment status, biomarker findings such as CD47 overexpression as a potential predictive biomarker, and data presented at major oncology and immunotherapy conferences, including meetings of the Society for Immunotherapy of Cancer (SITC), the American Society of Hematology (ASH) and the European Society for Medical Oncology (ESMO).
For ALX2004, company announcements highlight preclinical data, poster presentations at scientific conferences such as the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, and updates from the ongoing Phase 1 first-in-human trial in EGFR-expressing solid tumors. These items typically describe dose-escalation progress, safety observations and the rationale for further clinical evaluation.
ALX Oncology also reports quarterly financial results and corporate updates via press releases and related conference calls, which are referenced in Current Reports on Form 8-K. Additional news may include participation in investor conferences, webcasts, and changes in leadership or board composition. Readers who follow ALXO news can use this page to track clinical milestones, data disclosures and corporate developments over time.
ALX Oncology has initiated the first Phase 2 study in collaboration with Merck, dosing the first patient in the ASPEN-03 trial. This trial evaluates the efficacy of ALX148 in combination with KEYTRUDA for treating advanced head and neck squamous cell carcinoma (HNSCC). ASPEN-03 is a randomized, open-label study building on promising data from the Phase 1 ASPEN-01 study, which led to Fast Track designation from the FDA for ALX148 in HNSCC. The trial aims to accelerate development in various cancer indications.
ALX Oncology (Nasdaq: ALXO) announced an upcoming oral presentation of their Phase 1b study results for ALX148 at the ESMO World Congress on Gastrointestinal Cancer, scheduled for July 3, 2021. The study evaluates ALX148 in combination with trastuzumab, ramucirumab, and paclitaxel for patients with advanced gastric or gastroesophageal junction cancer. This presentation may highlight the therapeutic potential of ALX148 and its impact on treatment outcomes for patients, while contributing to the ongoing clinical development of their immuno-oncology pipeline.
ALX Oncology announced the end of the post-grant review period for U.S. Patent 10,696,730 concerning the composition of matter for ALX148, effective March 30, 2021. This patent secures coverage for ALX148 until at least 2036, bolstering its intellectual property. ALX148 is designed to enhance anti-cancer therapy effectiveness, demonstrating promise in both solid tumors and hematologic malignancies. The patent reinforces confidence as the company prepares for Phase 2 studies in various cancer types, including myelodysplastic syndromes and head and neck cancers.
ALX Oncology Holdings Inc. (ALXO) reported its financial results for Q4 and FY 2020, highlighting progress with its lead candidate ALX148 in immuno-oncology. Positive Phase 1b data showed promise in treating solid tumors, including gastric and head and neck cancers. The company plans to report full Phase 1b results and initiate multiple clinical trials in 2021, including two Phase 2 studies in HNSCC and a collaboration with Zymeworks. Despite these advancements, the company reported a net loss of $50.9 million for FY 2020, a significant increase from $23.3 million in 2019.
ALX Oncology (Nasdaq: ALXO) announced the appointment of Sophia Randolph, M.D., Ph.D., to its Board of Directors. As the current Chief Medical Officer, Dr. Randolph has over 15 years of biopharmaceutical experience, including leadership roles at Pfizer and Merck. Her expertise will enhance the board's capabilities as the company prepares for multiple clinical trials this year. This strategic addition aims to strengthen corporate strategy and drive clinical development of ALX148, a promising treatment targeting the CD47 checkpoint pathway.
ALX Oncology (Nasdaq: ALXO) has partnered with Tallac Therapeutics to co-develop a novel cancer immunotherapeutic, SIRPα TRAAC. This collaboration aims to create a first-in-class anti-SIRPα antibody conjugated to a TLR9 agonist, enhancing the company’s immuno-oncology pipeline targeting the CD47 checkpoint pathway. Both firms will equally share development costs and potential profits. The initiative is set to potentially revolutionize cancer treatment by leveraging innate and adaptive immune responses. A conference call is scheduled for March 5, 2021, to discuss further details.
BURLINGAME, Calif., March 02, 2021 – ALX Oncology Holdings Inc. (Nasdaq: ALXO) announced participation in a fireside chat at H.C. Wainwright’s Global Life Sciences Conference on March 9-10, 2021. Jaume Pons, Ph.D., and senior executives will provide insights during the virtual event. A prerecorded chat is set to release on March 9, 2021, at 7:00 a.m. Eastern Time, accessible via ALX Oncology's website. ALX Oncology focuses on immuno-oncology, developing therapies to block the CD47 checkpoint pathway, with its lead candidate ALX148 showing promising clinical results.
ALX Oncology Holdings Inc. (Nasdaq: ALXO) announced key milestones for 2021 following a successful 2020, which included an IPO and a secondary offering that raised approximately $394 million. The company initiated clinical trials for its lead candidate, ALX148, showing promising data in treating various cancers. Upcoming milestones include the initiation of multiple Phase 1 and 2 trials, with significant data readouts expected. ALX Oncology's cash reserves are projected to sustain operations through 2024, supporting ongoing clinical development and collaborations.
ALX Oncology (Nasdaq: ALXO) announced that Jaume Pons, Ph.D., its CEO, will present a company overview at the 39th Annual J.P. Morgan Healthcare Conference on January 12 at 10:50 am ET. The presentation will be accessible via a live webcast, available on the Investors section of ALX Oncology’s website. Following the event, a replay of the webcast will be archived for 30 days. ALX Oncology focuses on developing therapies that block the CD47 checkpoint pathway, with its lead candidate, ALX148, showing promise in treating various cancers.
ALX Oncology Holdings Inc. (NASDAQ: ALXO) has been selected for addition to the NASDAQ Biotechnology Index, effective prior to market open on December 21, 2020. The NASDAQ Biotechnology Index tracks biotechnology and pharmaceutical companies on NASDAQ, calculated under a modified capitalization-weighted methodology. ALX Oncology focuses on therapies that block the CD47 checkpoint pathway, with its lead candidate, ALX148, showing promising clinical responses for various malignancies.
FAQ
What is the current stock price of Alx Oncology Holdings (ALXO)?
What is the market cap of Alx Oncology Holdings (ALXO)?
